NCT06344767View on ClinicalTrials.gov

Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor

CompletedOBSERVATIONAL

Enrollment

19

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

May 5, 2024

Study Completion Date

May 5, 2024

Conditions

Breast Cancer

Trial Locations (1)

200032

China,Shanghai, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT06344767 - Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor | Biotech Hunter | Biotech Hunter